Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Cash from Operations: 2018-2024

Historic Cash from Operations for Therapeutics (RAPT) over the last 7 years, with Dec 2024 value amounting to -$83.3 million.

  • Therapeutics' Cash from Operations rose 62.38% to -$10.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$83.3 million, marking a year-over-year increase of 14.17%. This contributed to the annual value of -$83.3 million for FY2024, which is 14.17% up from last year.
  • As of FY2024, Therapeutics' Cash from Operations stood at -$83.3 million, which was up 14.17% from -$97.0 million recorded in FY2023.
  • Over the past 5 years, Therapeutics' Cash from Operations peaked at -$40.5 million during FY2020, and registered a low of -$97.0 million during FY2023.
  • Its 3-year average for Cash from Operations is -$83.7 million, with a median of -$83.3 million in 2024.
  • In the last 5 years, Therapeutics' Cash from Operations crashed by 50.71% in 2021 and then climbed by 14.17% in 2024.
  • Therapeutics' Cash from Operations (Yearly) stood at -$40.5 million in 2020, then plummeted by 50.71% to -$61.0 million in 2021, then dropped by 15.97% to -$70.8 million in 2022, then tumbled by 37.13% to -$97.0 million in 2023, then rose by 14.17% to -$83.3 million in 2024.